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Abstract: 
Given medical and social advances, the life expectancy of individuals with intellectual 
disability (ID) has increased dramatically, leading to a generation of older individuals with 
such disabilities. This review focuses on the pharmacological treatment of behavioral and 
psychiatric symptoms and disorders in older persons with ID. Older adults with ID often 
present with medical co-morbidities and mental health issues. Medication management of 
behavioral and psychiatric problems is complicated by a higher risk for adverse events, lack 
of decision-making capacity, and complex care networks. Some studies have shown that 
persons with ID and co-morbid mental disorders are undertreated in comparison to 
individuals with similar disorders in the general population, resulting in poorer outcomes. 
However, older adults with ID are also at risk of polypharmacy and older age is a risk factor 
for development of side-effects. A general principle is that medication treatment for 
psychiatric disorders in older persons with ID should be started at low dosages and be 
increased cautiously while monitoring response and side-effects. The use of psychotropic 
drugs for older persons with ID and behavioral problems remains controversial, particularly 
in those with dementia.  
 
Key points:  
• The growing population of older persons with ID has an increased risk for aging 
related health issues such as dementia, on a background of lifelong disabilities and 
physical health and psychiatric co-morbidities. 
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• Medication management of behavioral and psychiatric problems may be complicated 
by a higher risk for adverse events, lack of decision-making capacity, and complex 
care networks.  
• Medication management of specific conditions is however beneficial, but in general, 
medication should be started at low doses, with careful titration against response, 
and regular monitoring for side-effects. 
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1. Introduction 
Intellectual Disability (ID) is defined by the World Health Organization (WHO) as significant 
cognitive impairment associated with impairment of skills manifested during the 
developmental period. Cognitive impairment in people with ID is categorized as two standard 
deviations below the norm for intellectual quotient (IQ) with a level below 70 in the ID range. 
The development of social and adaptive skills is central in the definition of ID where the 
person requires support to maintain their level of functioning. Such deficits must have their 
origins in childhood, which contrasts with cognitive impairment acquired in adulthood. 
Classification systems categorize levels of IQ in to mild, moderate, severe, and profound. In 
general, people with mild ID require less support in daily living skills than others but they are 
often more vulnerable to exploitation by others and engage in more high risk lifestyle 
activities for example, cigarette smoking. People with intellectual impairment comprise 
between 2.5% to 3% of the general population based on statistical estimates in the 
population where ID is two standard deviations below the norm for IQ, but  the global 
prevalence estimate of ID (i.e. intellectual and functional impairment) is 1.03%  (1). 
ID is associated with greater degrees of health inequalities than in the general population 
and people have more co-morbid conditions affecting all body systems especially the 
nervous system (2). The prevalence of epilepsy for example, is greater in people with ID 
than in the general population (3).  The prevalence of mental disorders and behavioral 
problems associated with associated disorders such as autism is greater in people with ID 
(4). Therefore, people with ID are, from childhood, more likely to require drug therapy to 
manage such  long-term conditions and as such are exposed to the risks of using 
medication throughout their lives.  
The life expectancy of people with ID has risen over the past 50 years (5) which could be 
due to advances in medical technology and improved social care benefitting people with 
moderate to severe ID. Changes in societal attitudes towards people with ID and awareness 
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of health inequalities have also had beneficial effects. The life expectancy of people with 
Down syndrome (DS) has risen from 12 years in the 1940s to 60 years currently largely 
because of cardiac surgery interventions (6). In spite of this, people with ID continue to die 
younger than their peers in the general population which is in part due to health and social 
factors that may be amenable to change (7). Nevertheless, there are increasing numbers of 
older adults with ID who may require considerable care inputs.  The average annual cost of 
care for older individuals with ID in the UK is approaching £50,000 ($71,952; €54,034 at 
2013 rates for purchasing power parity), most of which is accounted for by personal care 
rather than health care costs, with mental health problems being an important predictor of 
costs)(8). Appropriate treatment and management of behavioral and psychiatric symptoms 
may therefore help to reduce the burden on caregivers as well as the cost of care.    
In this review, we will focus on the behavioral and psychiatric symptoms associated with 
aging in ID and the implications for medication management of these conditions in this 
population.  
 
2. Physical health issues  
A review of medication management in the ID population would not be complete without 
acknowledging the complex health needs of this population, which affect the selection of 
treatments for behavioral and psychiatric symptoms, and their effectiveness and tolerability.  
People with ID are more vulnerable to developing acute and chronic health problems for a 
variety of reasons related to either dependency as a consequence of ID, or to lifestyle 
factors for example, diet. An example of an acute health condition is the development of 
bronchopneumonia in a person with severe ID who has difficulties swallowing because of 
impaired reflexes. Older people with ID are more disposed to long-term conditions such as 
diabetes mellitus(9). Their management often requires drug interventions in the long-term 
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and thus exposing them to the side effects of medication over a long period of time as they 
age.  
People with ID often use combinations of medication that potentially interact with each other 
and have implications for other drugs added to current drug regimens. Clinicians need to be 
aware of the regimens that people use when prescribing new medication because of the 
pharmacokinetics of drugs that could affect the metabolism of other agents through enzyme-
induction or competitive binding to proteins thus affecting serum levels of drugs. Equally, 
clinicians need to consider the impact of weight-inducing medication on the       long-term 
health of the person and their subsequent quality of life. 
People with ID experience the same range of physical and mental health difficulties as in the 
general population but their level of functioning and cognitive impairments may predispose 
them to developing health problems. The rates of cardiovascular diseases in older adults 
with ID are  similar to those in the general population (9)(10)  while  neurological disorders, 
especially epilepsy occur at higher rates in people with ID (3). Overweight and obesity is 
also an increasing problem (9). In a recent large scale survey of older adults (age 55+) with 
ID in Europe, rates of smoking and use of alcohol were lower than in the general population 
but were higher with older age. More than 60% of older adults with ID had a sedentary 
lifestyle. Cataract, hearing disorder, diabetes, hypertension, osteoarthritis/arthrosis, and 
osteoporosis were positively associated with advancing age in those with ID, but rates of 
epilepsy declined with age (11). The aetiological factors for these health problems are multi-
factorial based in the etiology of the ID for example neurological development, or in 
environmental and social factors such as poor housing or impoverished diet and sedentary 
lifestyle.  
3. General issues regarding medication management in persons with ID  
Prescription of medication for the treatment and management of behavioral and psychiatric 
symptoms in persons with ID requires careful consideration. A full discussion of all the 
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issues is beyond the scope of this review, and has been reviewed elsewhere (12,13). The 
general principles of medication treatment of psychiatric disorders in persons with ID 
include:   
- Decision making capacity should be assessed, and if the person does not have 
capacity to decide about their own treatment, appropriate legal and ethical 
frameworks should be followed to enable treatment depending on the jurisdiction   
- Safe management and dispensing of medication should be carefully considered, and 
the use of blister packs, dosette boxes and medication alarm systems may be useful,  
as well as identifying a responsible person to assist with appropriate management of 
medication  
- Persons with ID often have complex care networks and it is important to inform all 
involved persons of any changes of  treatment  
- Side effects and response to treatment should be monitored, using standardized 
instruments if possible, with due consideration to the communication needs of the 
individual. The carers of those with limited communication abilities should be 
provided with clear instructions on how to monitor for side effects.   
 
4. Mental health disorders in older adults with ID  
Mental health disorders have a greater prevalence among people with ID with higher rates of 
psychosis, dementia, and mood disorders than the general population (4)(14)(15). Drug 
management of such disorders in people with ID is important because of the benefits to the 
person in treating the disorders but the choice and management of medication should be 
undertaken by a clinician knowledgeable in the mental healthcare of people with ID. 
However, there is very little evidence to guide prescribing of behavioral and psychiatric 
symptoms in this population because people with ID have been historically 
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underrepresented in randomized controlled medication trials (16). We will summarize 
generally accepted recommendations, and highlight specific findings if available.    
4.1. Treatment of mood disorders in older adults with ID 
Depression is common in adults with ID (4) and is more likely to follow a chronic course (17).   
In older adults with ID, increased depressive symptoms were significantly and positively 
correlated with age, and were also associated with chronic diseases such as heart failure, 
stroke, chronic obstructive pulmonary disease, coronary artery disease, diabetes mellitus 
and malignity in the previous 5 years (18).  In a large survey of depression in older adults 
with ID (aged 50 and older) in the Netherlands, major depressive disorder was prevalent in 
7.6% (95% CI: 5.2–11.0), anxiety disorders in 4.4% (95% CI: 2.6–7.0) and both disorders in 
0.7% (95% CI: 0.2–1.6). There was no relationship with gender, age or level of ID (19). 
In Taiwan, patients with ID and Bipolar affective disorder were younger than patients with 
Bipolar Affective Disorder without ID, but had longer periods of  hospitalization and were 
more likely to remain as in-patients, possibly due to receiving significantly lower dosages of 
medication such as antipsychotics, mood stabilisers and lithium (20). These findings are 
unlikely to be unique to Taiwan and suggest that mood disorders remain under-recognised 
and under-treated in persons with ID, which affect longer term outcomes. However, use of 
antidepressants particularly selective serotonin reuptake inhibitors (SSRIs)  have been 
increasing in the ID populations since the mid-1990s  in the US (21). The increased use of 
SSRIs with fewer side effects was interpreted as evidence for improving skill in diagnosing 
and treating depressive disorders in this population. 
We were not able to identify specific studies or guidelines for medication treatment of 
depression in older individuals with ID. In general, the treatment guidelines for depression in 
the general population are appropriate to use, including the UK’s NICE guideline (22) and 
Management of psychiatric symptoms in older persons with ID  
the American Psychiatric association’s practice guideline (23).  
 
4.2. Use of antipsychotic drugs in older adults with ID  
A large survey of antipsychotic prescribing to 2319 adults with ID (all ages) in the UK found 
that the commonest indications were for psychotic illness (42%) and anxiety (42%), while 
behavioral problems such as aggression (38%), threatening behavior (30%) and self-harm 
(13%) were also common indications (24). Risperidone was the most prescribed 
antipsychotic, particularly for agitation and anxiety, at a median dose of 2mg per day, 
followed by olanzapine which was most often prescribed for psychotic symptoms. The 
second most common drug for psychosis was quetiapine. Use of older antipsychotics was 
common, particularly chlorpromazine which was used for overt aggression, and haloperidol 
for agitation and anxiety. This survey was undertaken before use of aripiprazole became 
more common in the UK, and it is likely that this drug may increasingly be used for 
psychosis or behavioral disturbances associated with ID or autism following some evidence 
of efficacy (25)(26). Guidelines have been produced for the use of newer antipsychotic drugs 
in persons with ID (27), which included practical drug review checklists, as well as for 
clozapine (28). These drugs need to be used cautiously in older adults with ID, particularly in 
those with co-morbidities:  
• dementia and cerebrovascular disease, which are relative contraindications for newer 
antipsychotics due to an increased risk for stroke 
• olanzapine and quetiapine have potential antimuscarinic activity, which in combination 
with other medications with antimuscarinic activity may significantly impact on cognition 
in older individuals with ID, as well as cause problems with gastrointestinal motility, 
urinary retention, and narrow-angle glaucoma (27).  
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• clozapine, quetiapine, olanzapine and risperidone may cause hypotension and clinicians 
should use these drugs cautiously in older adults with ID prescribed with 
antihypertensives. 
• Metabolic syndrome is a well-known complication of newer antipsychotics (particularly 
olanzapine and clozapine), and risk factors such as obesity and diabetes are common in 
older adults with ID, particularly those with mild intellectual impairment.  Concomitant use 
of medications known to elevate blood glucose or cause weight gain should be avoided 
as far as is possible in older adults with ID. It is also recommended to document weight, 
BMI, glucose levels, glycosylated hemoglobin levels, electrolytes and liver function tests 
before starting these drugs (27) though often it is not done in practice (29).  The use of 
newer (atypical) antipsychotics was associated with higher diastolic blood pressure and 
elevated fasting glucose in adults prescribed antipsychotic drugs for more than 1 year 
(30).       
 
4.3.  Medication management of problem behavior in older adults with ID 
There is some evidence for the use of medication for problem behavior in adults with ID 
particularly those with co-morbid autism (13). The best evidence is for risperidone, with 
multiple trials showing its efficacy (26). The management of problem behavior  in people with 
ID can include the use of other medications to help manage behavior that could be attributed 
to mental disorder for example, anxiety, mood disorder, or psychosis. The etiological cause 
of the problem behavior can be difficult to elucidate and medication is often used to manage 
it without clear indications for example, anti-psychotic drugs can be used for their sedative or 
anxiolytic properties rather than to treat psychotic signs. In doing this, the person may be 
exposed to the adverse effects of medication particularly if used over a prolonged period of 
time with the potential of interacting with other drugs, particularly in older persons. 
Furthermore, a controlled discontinuation study of long-term antipsychotics for behavioral 
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disturbance in persons with ID (aged 15 - 66; n = 98), in which 43 achieved complete 
discontinuation, showed that a significant proportion of individuals benefited from reduction 
or withdrawal of the medication with improvement in clinical symptoms (30). Most guidelines 
concerning medication use for problem behavior therefore recommend careful titration 
against response, regular monitoring for side-effects and using short treatment periods if 
possible (12). In general, one medication should be used at a time, within standard 
recommended dosage range and the opportunities for monotherapy should be exhausted 
before a combination therapy is considered. Appropriate follow-up visits must be arranged, 
and the potential for dosage reduction or discontinuation of medication should be regularly 
considered during the course of treatment (16).  
5. Dementia in older adults with ID 
As the average life expectancy in the ID population increases, so does the number of 
individuals experiencing complications of older age, such as dementia. Dementia is defined 
as a chronic, progressive mental disorder which adversely affects higher cortical functions 
including memory, language and orientation (31) and associated with increasing morbidity 
and mortality and imposes significant costs (32). It is therefore important that evidence-
based treatments for dementia in ID are developed and evaluated.  
Dementia in ID often has an atypical presentation. Changes in behavior or personality may 
precede the traditional cognitive symptoms, particularly in those with more severe ID and 
DS, and the onset of seizures is also common (8). 
A number of anti-dementia medications including acetlycholinesterase inhibitors (AIs) such 
as donepezil, rivastigmine and galantamine and the N-methyl-D-aspartate (NMDA) 
antagonists memantine  have been developed and there is a strong evidence-base to 
support their prescription in the non-ID population (33). These medications are noted to have 
a beneficial effect on the behavioral and psychiatric symptoms of dementia in addition to 
maintaining cognitive functions in the short to medium term (34). The prescription of anti-
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dementia medication is supported by national and international guidance including that in the 
UK (35), USA  (36) and Europe (37).  
AIs and NMDA antagonists are not believed to have disease modifying properties and are 
therefore not used to prevent the long-term histopathological progression of disease. 
However in the short to medium term they have been shown to slow the clinical 
deterioration.  
5.1. Management of dementia in Down syndrome 
Down syndrome (DS) is neuropathologically associated with the risk of developing an 
Alzheimer-like dementia (38). Donepezil, from the anticholinesterase class of medications, is 
the most commonly prescribed anti-dementia medication in this population. A review of the 
literature found a few small controlled studies (39)(40)(41) which confirm that donepezil is 
well tolerated in the DS population. These studies have some methodological flaws including 
the small sample size, choice of controls, and length of follow-up. Other than commenting on 
safety and the side effect profile, it is not possible to draw conclusions on the efficacy of 
donepezil on cognition or functioning, or the control of associated behavioral and psychiatric 
symptoms in the DS dementia population.  Further evidence is required, including from non-
randomized designs as it may not be possible to complete further randomised control 
studies.  
There are no published studies on the efficacy of galantamine in the DS population.  
A recent small non-randomized observational study showed a significant difference in 
cognitive functioning (p=0.048) and behavior (p=0.05) between a non-treatment group with 
DS and those prescribed rivastigmine either as oral or transdermal formulation (42). The 
authors noted that transdermal rivastigmine had improved compliance and was well 
tolerated in the DS population. Another small placebo controlled trial of rivastigmine in older 
adults with DS showed a reduction in the rate of deterioration on markers of cognition and 
behavior between the treatment and control groups after 24 weeks (43). The differences 
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between the control and treatment group were not statistically significant.  Both of the above 
studies have the limitations of being small and having short follow-up periods. 
The current literature on memantine does not support its use in clinical practice in DS. A 
recent prospective double-blind, randomised control trial compared memantine with a 
placebo in patients with DS (44). All participants in the study were over 40 years of age of 
which a third had a diagnosis of dementia. There was no statistical significance between the 
groups at one year on measures of functioning, behavior or cognition. The authors 
concluded that memantine is not effective in the treatment of dementia in the DS population. 
5.2. Management of dementia in the Non-DS ID population 
People with DS  are the population among people with ID who are most at risk of developing 
dementia. Dementia may also be more common in older adults with ID who do not have DS, 
with prevalence rates of up to 18% in those aged 65 and older (14). Incidence rates peak at 
age 70-75 (45).  
However, among people with ID but who do not have DS (non-DS ID) there is no published 
research on the pharmacological treatment of dementia despite a recent estimate of the 
incidence of dementia among them being up to 4 times higher than the general population 
(45). Current clinical practice varies widely with clinicians often referring to the evidence 
base for the DS population and the non-ID population. Clinicians, carers, and patients often 
lack awareness of the early signs of dementia which can result in a delay in offering 
dementia-specific treatments (46).  
5.3. Management of behavioral and psychiatric symptoms associated with 
dementia in ID 
Dementia in ID is frequently associated with co-morbidities including psychiatric 
presentations, for example depression, and behavioral problems (8). Some of these 
psychiatric co-morbidities including problem behavior may be noted to improve with the 
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prescription of dementia medication listed above. Antipsychotic drugs have been widely 
used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease in the 
general population, but following a large randomized trial it was concluded that adverse 
effects offset advantages (47). In some countries such as the UK, recent guidelines 
consequently suggested that antipsychotics are overused in older adults with dementia in 
the general population and that the potential benefit of their use is likely to be outweighed by 
the adverse effects in many cases. Whilst not prohibiting use of such drugs, a key 
recommendation was to avoid the prescription of newer antipsychotics in adults with 
dementia (48). Pharmacological treatment of any co-morbidity would therefore need to be in 
accordance with the guidance on managing co-morbidity in general guidance by the relevant 
national body such as the American Psychiatric Association (USA) or the Royal College of 
Psychiatrists (UK).                
Medical co-morbidities are a common cause of mortality in the older adult ID population and 
require prompt review in any person presenting with a change in behavior. The prescriber 
should also be aware of the associated risk of polypharmacy and drug interactions in this 
population. Although outside the scope of this review, changes in support plans and access 
to psychological interventions both have an important role in the treatment of the behavioral 
and psychiatric symptoms of dementia (49).  
Sleep difficulties are noted to increase in older age groups, especially in those with dementia 
(50). Behavioral difficulties secondary to the day-night routine is common. Melatonin is noted 
to be effective in reducing sleep onset latency in the ID population (51) although there are no 
published trials reviewing the safety or efficacy of melatonin prescription in the ID dementia 
population. 
 
6. Polypharmacy and prescribing patterns  
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In a large study of psychotropic prescribing patterns in the USA comparing persons with ID 
with a dual diagnosis of co-morbid psychiatric disorders against those with normal ability 
with psychiatric diagnoses, it was found that antidepressants and antipsychotics were 
prescribed at lower rates for those with an ID, suggesting that psychiatric conditions in the ID 
population were often undertreated.  However, polypharmacy rates were higher for adults 
with ID (52) and rates of prescribing of antipsychotics and antidepressants have been 
increasing over the past few decades (21).  
Prescribing patterns are changing with prescribers moving away from medication 
management of behavioral issues as found in a recent study of  psychotropic drug 
prescribing in adults with ID of all ages (mean age 49 years) in New York State (21).  
Although 58% of these adults with ID were prescribed one or more psychotropic drug, in 
most cases the indication was a diagnosed  co-morbid mental disorder and only 13% were 
prescribed psychotropic drugs solely for control of behavioral problems (21). Age had no 
effect on the likelihood to be prescribed antipsychotics.  
One group from the Netherlands described the side effect profiles associated with longer 
term (more than 1 year) antipsychotic use for behavioral problems in persons with ID with a 
mean age of 49.8 years (30). Extrapyramidal symptoms were present in 53%, overweight 
and obesity in 46%, and the metabolic syndrome in 11%. Hyperprolactinaemia was present 
in 17%. Older age and more severe ID were associated with increased rates of side-effects, 
particularly dyskinesia.   
7. Conclusions and further research 
Older adults with ID often present with medical co-morbidities and mental health issues. 
Many older individuals may have been prescribed long-term medication for psychiatric 
disorders such as autism but they may be more sensitive to the development of side effects 
particularly of anti-psychotics.  Some studies have shown that persons with ID and co-
morbid mental disorders are undertreated in comparison to individuals with similar disorders 
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in the general population resulting in poorer outcomes. However, older adults with ID are 
also at risk of polypharmacy and older age may be a risk factor for development of some 
side-effects. A general principle is that medication treatment for psychiatric disorders in older 
persons with ID should be started at low dosages and be increased cautiously while 
monitoring response and side-effects. The use of psychotropic drugs for persons with ID and 
behavioral problems remain controversial, particularly in older adults with dementia, and 
current guidelines are to use alternative treatments such as behavioral interventions as first-
line option. If psychotropic drugs are used they  should be carefully monitored and used for 
short periods. It remains to be seen whether the latest generation of antipsychotics such as 
aripiprazole are safer or better tolerated in older persons with ID.   
Dementia is a common problem in this population and medication treatments for dementia in 
those with ID are broadly safe and well-tolerated. Sleep problems may respond to treatment 
with melatonin.  There remains however a lack of strong evidence to support the clinical 
effectiveness of most medication treatments in this population given the current lack of well-
designed, adequately powered studies.   
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